Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Objective: To improve poor medication adherence in schizophrenic patients, long-acting injectable (LAI) antipsychotics are used. However, it has not yet become common in Japan. Recently, aripiprazole LAI was approved for alternative injection into the deltoid muscle in addition to the gluteal muscle. The acceptance for the proposal to switch from gluteal to deltoid injections of aripiprazole LAI was investigated. Methods: The subjects were 32 outpatients with schizophrenia who had continuously received aripiprazole LAI administration into the gluteal muscle for ≥ 6 months. In the patients who had continued deltoid injection for 3 months after switching, the changes in the pain and shame in comparison with gluteal injections were evaluated. Results: Switching to the deltoid injection was chosen by 17 out of 32 patients. Three months later, 9 patients were still receiving deltoid injections with highly rated satisfaction. The main reasons for switching to deltoid injections included the pain and shame associated with gluteal injections. The main reason for returning to the gluteal injection was the pain experienced from the injection in the deltoid. Conclusion: The option to select the injected area was based on the amount of pain in the deltoid and gluteal sites, leading to the widespread use of aripiprazole LAI.
Abstract
Objective: To improve poor medication adherence in schizophrenic patients, long-acting injectable (LAI) antipsychotics are used. However, it has not yet become common in Japan. Recently, aripiprazole LAI was approved for alternative injection into the deltoid muscle in addition to the gluteal muscle. The acceptance for the proposal to switch from gluteal to deltoid injections of aripiprazole LAI was investigated. Methods: The subjects were 32 outpatients with schizophrenia who had continuously received aripiprazole LAI administration into the gluteal muscle for ≥ 6 months. In the patients who had continued deltoid injection for 3 months after switching, the changes in the pain and shame in comparison with gluteal injections were evaluated. Results: Switching to the deltoid injection was chosen by 17 out of 32 patients. Three months later, 9 patients were still receiving deltoid injections with highly rated satisfaction. The main reasons for switching to deltoid injections included the pain and shame associated with gluteal injections. The main reason for returning to the gluteal injection was the pain experienced from the injection in the deltoid. Conclusion: The option to select the injected area was based on the amount of pain in the deltoid and gluteal sites, leading to the widespread use of aripiprazole LAI.
참고문헌 (21)
- Weiden PJ, "Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia", Psychiatr Serv, 55, pp.886~891 (2004)
- Leucht S, "Maintenance treatment with antipsychotic drugs for schizophrenia", Cochrane Database Syst Rev, (5), pp.CD008016~ (2012)
- Lacro JP, "Prevalence of and risk factors for medication nonadherence in patients with schizophrenia : a comprehensive review of recent literature", J Clin Psychiatry, 63, pp.892~909 (2002)
- National Collaborating Centre for Mental Health(UK), "Psychosis and schizophrenia in adults : treatment and management", National Institute for Health and Care Excellence(UK), ~ (2014)
- Leucht C, "Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials", Schizophr Res, 127, pp.83~92 (2011)
- Olivares JM, "Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain : results from the electronic Schizophrenia Treatment Adherence Registry(e-STAR)", Eur Psychiatry, 24, pp.287~296 (2009)
- Llorca PM, "Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia(ALTO)study", Eur Psychiatry, 52, pp.85~94 (2018)
- Jaeger M, "Attitudes towards long-acting depot antipsychotics : a survey of patients, relatives and psychiatrists", Psychiatry Res, 175, pp.58~62 (2010)
- Kane JM, "Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia", J Med Econ, 16, pp.917~925 (2013)
- Potkin SG, "Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia", Expert Opin Pharmacother, 17, pp.395~407 (2016)
- Otsuka Pharmaceutical Co., Ltd, "The manual of ABILIFYⓇ(aripiprazole)" (2016), Otsuka Pharmaceutical Co., Ltd
- Raoufinia A, "Aripiprazole once-monthly 400 mg : comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration", Int J Neuropsychopharmacol, 20, pp.295~304 (2017)
- Yin J, "Paliperidone palmitate long-acting injectable given intramuscularly in the deltoid versus the gluteal muscle: are they therapeutically equivalent?", J Clin Psychopharmacol, 35, pp.447~449 (2015)
- Heres S, "Patients’ acceptance of the deltoid application of risperidone long-acting injection", Eur Neuropsychopharmacol, 22, pp.897~901 (2012)
- Busner J, "The clinical global impressions scale:applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
- Geerts P, "Attitudes towards the administration of long-acting antipsychotics : a survey of physicians and nurses", BMC Psychiatry, 13, pp.58~ (2013)
- Sugawara N, "Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan", Neuropsychiatr Dis Treat, 15, pp.205~211 (2019)
- Hough D, "Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.1022~1031 (2009)
- Overall JE, "The brief psychiatric rating scale", Psychol Rep, 10, pp.790~812 (1962)
- Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Leucht S, "Linking the PANSS, BPRS, and CGI : clinical implications", Neuropsychopharmacology, 31, pp.2318~2325 (2006)